| Jul'19 | Jul'18 | Jul'17 | Jul'16 | |||
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net Loss | ||||||
-4,924 | -12,076 | 138 | 710 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
1,779 | 1,698 | 1,669 | 1,643 | |||
Deferred income taxes | ||||||
-19 | 8,859 | -295 | 368 | |||
Interest income on Series D Convertible Note | ||||||
-848 | - | - | - | |||
Realized gain on marketable securities | ||||||
- | 0 | 0 | 0 | |||
Interest income | ||||||
37 | -104 | -113 | 0 | |||
Net gain on sales of marketable securities | ||||||
330 | - | - | - | |||
Unrealized (gain) loss on investments - Hedge Funds | ||||||
907 | - | - | - | |||
Provision for doubtful accounts | ||||||
122 | 0 | 0 | 82 | |||
Non-cash compensation | ||||||
372 | 657 | 0 | 0 | |||
Amortization of debt discount | ||||||
17 | - | - | - | |||
Realized gain on disposal of bonus shares | ||||||
- | 246 | 0 | 0 | |||
Loss on disposal of fixed assets | ||||||
- | -13 | 0 | 0 | |||
Net gain resulting from foreign exchange transactions | ||||||
- | 32 | 86 | -13 | |||
Change in assets and liabilities: | ||||||
Trade accounts receivable | ||||||
285 | 23 | 7 | 109 | |||
Prepaid expenses and other current assets | ||||||
86 | 258 | 130 | -323 | |||
Write off of patents | ||||||
-76 | - | - | - | |||
Other assets | ||||||
-275 | 586 | 481 | -30 | |||
Accounts payable and accrued expenses | ||||||
533 | -35 | 50 | 9 | |||
Due to Related Party | ||||||
654 | 2 | -2,626 | -3,041 | |||
Due to/from related parties | ||||||
280 | - | - | - | |||
Other current liabilities | ||||||
3 | -10 | 11 | 17 | |||
Accrued Interest - Related Party | ||||||
649 | - | - | - | |||
Other liabilities | ||||||
104 | 118 | 21 | 27 | |||
Net cash used in operating activities | ||||||
-3,132 | -1,815 | -1,623 | 72 | |||
Investing activities | ||||||
Purchases of property and equipment | ||||||
399 | 710 | 1,820 | 1,553 | |||
Proceeds from sale and maturity of marketable securities, net | ||||||
25,031 | 6,670 | 0 | 0 | |||
Investment in Rafael Pharmaceuticals | ||||||
- | 151 | 9,400 | 2,100 | |||
Cash advances to IDT Corporation, net of repayments | ||||||
- | 1,700 | 0 | 0 | |||
Investment in Rafael Pharmaceuticals | ||||||
55,870 | - | - | - | |||
Net cash used in investing activities | ||||||
-31,238 | 4,109 | -11,220 | -3,653 | |||
Financing activities | ||||||
Contribution from noncontrolling interest of consolidated entity | ||||||
4,587 | - | - | - | |||
Repayment of Loan from Rafael Pharmaceuticals | ||||||
3,335 | - | - | - | |||
Proceeds from exercise of options | ||||||
190 | - | - | - | |||
Proceed from sale of shares | ||||||
7,777 | - | - | - | |||
Repayment of note payable | ||||||
- | 0 | 0 | 6,353 | |||
Proceeds from sale of interest and rights in Rafael Pharmaceuticals, Inc. to Howard S. Jonas | ||||||
- | 0 | 1,000 | 0 | |||
Proceeds from sale of member interests in CS Pharma Holdings, LLC | ||||||
- | 0 | 10,000 | - | |||
Proceeds from deposit on sale of 10% interest in Rafael Holdings, Inc. to Howard S. Jonas | ||||||
- | 864 | - | - | |||
Cash advances from IDT Corporation, net of repayments | ||||||
- | 886 | 11,260 | 6,618 | |||
Proceeds from convertible notes payable - Related Party | ||||||
15,000 | - | - | - | |||
Net cash (used in) provided by financing activities | ||||||
30,889 | 1,750 | 22,260 | 265 | |||
Effect of exchange rate changes on cash and cash equivalents | ||||||
-298 | -3 | 0 | 3 | |||
Net decrease in cash and cash equivalents | ||||||
-3,779 | 4,047 | 9,417 | -3,313 | |||
Supplemental Schedule of Non-Cash Investing and Financing Activities | ||||||
Adoption effect of ASU 2016-01 | ||||||
39 | - | - | - | |||
Beneficial conversion feature of convertible debt - Related Party | ||||||
71 | - | - | - | |||
Debt and accrued interest converted to Series D Preferred Stock | ||||||
10,848 | - | - | - | |||
Related Party deposit utilized to purchase Class B Common Stock | ||||||
864 | - | - | - | |||
Cash payments made for taxes | ||||||
- | 0 | 63 | 24 | |||
Cash payments made for interest | ||||||
- | 0 | 0 | 31 | |||